Home Events Webinars Webinar: Phase 2 Clinical trial results of the Pan-PPAR Agonist Lanifibranor in NASH patients

Webinar: Phase 2 Clinical trial results of the Pan-PPAR Agonist Lanifibranor in NASH patients

In this webinar Prof. Sven Francque will be discussing the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment.

Speaker: Prof. Sven Francque
Host: Dr. Manuel Castro Cabezas
Co-host: Prof. Christophe Moreno

  • 00

    days

  • 00

    hours

  • 00

    minutes

  • 00

    seconds

Tags:

Date

01 Feb 2022

Time

5:00 pm - 6:00 pm

Local Time

  • Timezone: America/New_York
  • Date: 01 Feb 2022
  • Time: 12:00 pm - 1:00 pm
Category